ERBB2 and breast cancer: It should be noted that IHC results of 327 breast cancers from Kao et al. were not available, and we modified the method from Karn et al. [37] and fitted two finite mixture models to derive clinical ER and HER2 status directly from the corresponding probesets; more details are given in the Methods S1.